Bachem Holding AG (BCHMY, BCHMF), a Swiss biotechnology company, on Thursday reported higher full-year 2025 net income compared with the previous year, proposed a dividend increase, and projected strong sales growth, an improved margin outlook, and higher capital expenditure for 2026.
For the full year 2025, net income increased to 148.79 million Swiss Franc from 120.25 million Swiss Franc in the prior year.
Earnings per share were 1.98 Swiss Franc versus 1.60 Swiss Franc last year.
EBITDA rose to 214.7 million Swiss Franc from 176.3 million Swiss Franc in the previous year.
Operating income or EBIT surged to 167.30 million Swiss Franc from 133.05 million Swiss Franc in the prior year.
Net sales increased to 695.07 million Swiss Franc from 605.26 million Swiss Franc in the previous year.
Further, the board proposed raising the dividend by 0.05 Swiss Franc to 0.90 Swiss Franc per share, subject to approval at the April 2026 annual general meeting.
Looking ahead, the company expects full-year 2026 sales growth of 35% to 45% in local currencies, with the EBITDA margin projected in the low-30% range, and capital expenditure planned at more than CHF 400 million for the year.
On Wednesday, Bachem Holding AG closed trading, 0.72% lesser at CHF 54.95 on the Swiss Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.